Why the study?
Does exenatide twice daily increase adverse events compared to placebo or insulin in patients with type 2 diabetes?
Population
5,594 intent-to-treat patients with type 2 diabetes pooled from 19 completed, randomized, controlled…
Comparison
Exenatide twice daily (5 μg and 10 μg) vs Pooled comparator (placebo and insulin)
Design
Meta-analysis
Follow-up
12-52 weeks (mean exposure time 166-171 days)
Authors
Loading...
Supports exenatide twice daily use with GI-focused counseling; confirms no excess serious adverse events or MACE risk in type 2 diabetes.
Does exenatide twice daily increase adverse events compared to placebo or insulin in patients with type 2 diabetes?
Exenatide twice daily is generally safe and well-tolerated in patients with type 2 diabetes, with gastrointestinal events being the most common adverse effect and no increased risk of major adverse cardiac events.
Gurney et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: